fusion of the brain is affected. To prevent episodes where cerebral blood flow (CBF) and oxygenation are compromised, vasopressor agents including ephedrine, phenylephrine, and norepinephrine are administered to maintain arterial pressure within what is considered to represent the cerebral autoregulatory range. 2 Frontal lobe oxygenation (S c O 2 ) can be monitored by near infrared spectroscopy (NIRS), and S c O 2 identifies the lower limit of cerebral autoregulation 3 and can be used to guide so-called individualized goal-directed fluid therapy. 4 Perioperative optimization of S c O 2 carries the potential to improve postoperative outcomes in cardiac 5 6 and elderly patients, 7 while a low preoperative S c O 2 might predict adverse postoperative outcomes. 8 S c O 2 is validated by correlation to a calculation of cerebral tissue oxygenation based on the arterial to internal jugular venous oxygen difference and taking changes in CBF into account. 9 Spatially resolved NIRS (SR-NIRS) intends to provide an absolute value for cerebral oxygenation and attenuates the superficial tissue contribution to S c O 2 by emphasizing light returning from 'deep' tissues.
explain the decrease in S c O 2 seen after administration of norepinephrine 11 and phenylephrine 12 -14 because these drugs do not affect CBF. 15 16 On the other hand, administration of ephedrine does not affect S c O 2 but its effect on extra-and intra-cerebral perfusion is unknown. 12 13 The hypothesis of the present study was that not only CBF but also external carotid and skin blood flow are maintained with the use of ephedrine. Furthermore, we took advantage of using two SR-NIRS machines to evaluate whether a large detector separation attenuates the influence of extracranial flow on S c O 2 , accepting that such a comparison involves the undisclosed algorithms used by the apparatus to derive at S c O 2 .
Methods
Ten healthy males (age 20-54 yr; height 175-180 cm; weight 74-102 kg) participated in the study that was approved by the local ethics committee [H-4-2010-132 (35774)] and conducted in accordance with the Declaration of Helsinki including the subjects' written and oral consent. First the subjects were familiarized with the experimental setting and then positioned in a hospital bed for 20 min before catheterization. Under local anaesthesia (2% lidocaine), a catheter (Edwards Lifesciences, Irvine, CA, USA) was inserted in the right internal jugular vein by the Seldinger technique and advanced to its bulb. 17 The position of the catheter was verified by an auditory response with quick infusion of saline and eventually by nociception related to the mastoid process. 18 A catheter (1.1 mm, 20 G) was inserted in the brachial artery of the nondominant arm, and a third catheter (Cavafix MT134, Braun, Melsungen, Germany) was advanced to the subclavian vein from a cubital vein and used for drug administration. Catheters were connected to a transducer (Edwards Life Sciences, Irvine, CA) placed at the level of the heart (5 cm below the sternum). From the transducer the catheters were connected to a monitor (Dialogue-2000 IBC-Danica Electronic, Denmark) for determination of mean arterial pressure (MAP) and heart rate (HR). Stroke volume (SV), cardiac output (CO), and total peripheral resistance (TPR) were derived according to Modelflow w technology (BeatScope; Finapres Medical System BV, Amsterdam, The Netherlands) taking weight, height, age, and gender into account. 19 Data were analogue-digital converted and sampled at 100 Hz (Powerlab, ADInstruments, Colorado Springs, CO, USA). Two SR-NIRS systems (Invos-5100c, Covidien, Mansfield, MA, USA and Foresight, CAS Medical Systems, Inc., Branford, CT, USA) assessed S c O 2 . Invos-5100c uses an emitter-detector distance of 3 and 4 cm and light at 730 and 808 nm, whereas Foresight applies emitter-detector separation of 1.5 and 5 cm and uses light at 690, 780, 808, and 850 nm. To avoid influence from supraorbital cutaneous blood flow and the frontal and sagittal sinuses, sensors were placed laterally 2-3 cm above the supraorbital edge over each hemisphere. 20 21 The sensors for the two devices were placed on the right or left side in randomized order. Skin oxygen saturation (S skin O 2 ) and blood flow (SkBF) were assessed close to the hairline by an integrated optode (VMS-OXY and VMS-LDF1, Moor Instruments, Axminster, UK) based on white light spectroscopy (400-650 nm) and laser Doppler flowmetry (785 nm) that is influenced by changes in tissue oxygenation and flow to a depth of 1-2 mm within an area of 9 mm 2 . The apparatus has a reported accuracy of 2% and 10 PU for S skin O 2 and SkBF, respectively. Blood flow in the right internal (ICAf) and blood flow in external carotid (ECAf) (n¼8) and vertebral arteries (VAf) (n¼6) were examined in randomized order by duplex ultrasonography (Vivid-i, GE Healthcare, Tokyo, Japan). Blood flow was examined 1.5 cm from the carotid bifurcation for ICA and ECA while blood flow in VA was determined between the transverse process of the C3 vertebra and the subclavian artery. We used the brightness mode to measure mean vessel diameter in a longitudinal direction and cross section. The Doppler velocity spectrum was subsequently identified by pulsed wave mode. The systolic and diastolic diameters were measured and the mean diameter was taken as [(systolic diameter×1/3)]+ [(diastolic diameter×2/3)]. The time-averaged mean flow velocity obtained in pulsed wave mode was measured by tracing average flow for each time phase and by calculating the time-averaged value across 45 cardiac cycles to eliminate the effects of ventilation. When recording blood flow velocity, care was taken to ensure that probe position was stable, that insonation angle did not vary and was smaller than 608, and that sample volume was focused at the centre of the vessel and covered its width. Mean blood flow velocity was calculated on the basis of velocity waveforms traced by the apparatus software. Flow was the cross-sectional area [p×(0.5×mean diameter) 2 ] times mean blood flow velocity: blood flow 60×mean blood flow velocity (cm s 21 )×area (cm 2 ), 22 which has an accuracy of 5%. 23 Furthermore, from the temporal ultrasound window, blood flow velocity in the middle cerebral artery (MCAv mean ) was determined by transcranial Doppler sonograph (2 MHz probe, Multi-Dop, DWL, Singen, Germany) with the best signal-to-noise ratio obtained at a depth of 44-56 mm, and the probe was secured by a headband.
Protocol
After catheterization, subjects rested supine for 30 min. Before infusion of either phenylephrine or ephedrine control measures were obtained for 15 min. Since the effect of ephedrine is prolonged while the effect of phenylephrine lasts for only minutes, administration was in a fixed order with phenylephrine (50 mg ml 21 ; 1 -1.75 mg per subject; n¼9) administered first. After 90 min ephedrine (1 mg ml 21 ; 50-135 mg; n¼9)
was administered when cardiovascular variables had returned to the basal level. Administration of the two drugs was titrated to achieve an 20 mm Hg increase in MAP. After 12-14 min of drug infusion, blood samples were obtained in pre-heparinized syringes, and were immediately analysed for arterial oxygen and carbon dioxide tension (Pa O 2 , Pa CO 2 ) and oxygen saturation (Sa O 2 , S j O 2 ; ABL700; Radiometer, Copenhagen, Denmark). We used an arterial to venous derived estimate of cerebral oxygenation (S av O 2 ) 24 :
Ephedrine and NIRS determined cerebral oxygenation During administration of ephedrine plasma catecholamines were determined to evaluate to what extent ephedrine influences plasma norepinephrine. Arterial blood was collected at the end of the infusion while control samples were from a separate day. Samples were immediately centrifuged for 5 min at 3000 rpm and placed in a 2808C freezer. Plasma norepinephrine was determined by high-performance liquid chromatography with electrochemical detection, using an amperometric detector (Antec Decade, Leiden, The Netherlands). The output was recorded on a computer (LCsolution, Simatzhu Corporation, Kyoto, Japan) and used to calculate the area under the curve.
Hyperventilation
To test whether SR-NIRS was sensitive to changes in frontal lobe tissue oxygenation, four subjects were asked to hyperventilate to reduce Pa CO 2 by 2 kPa. After 3-4 min, Pa CO 2 and Pa O 2 were determined.
Statistical analysis and data extraction
On the basis of a previous study, 15 the sample size of a paired t-test was indicated to be n¼6 (b¼0.9) to detect a change in S av O 2 of 8.6 (4.6)% observed with hypoxaemia in healthy humans. Differences between control and either phenylephrine or ephedrine were evaluated using a paired t-test in proc mixed SAS 9.2 (SAS Institute, Inc., Cary, NC, USA) with a significance level set to P,0.05. Averages were calculated over 60 s for each intervention at steady-state. The distribution of the raw data (i.e. mean, median, and skewness) was controlled by proc univariate in SAS, and the data are presented as absolute changes from baseline [standard deviation (SD)] in Table 1 and Figure 1 , and in Figure 2 as relative changes from baseline (95% confidence interval).
Results
Flow in carotid artery could not be obtained with a sufficient signal in one subject. Furthermore, one subject did not receive phenylephrine while ephedrine was not administered to another subject due to problems with the central catheter.
Measurements of SkBF and S skin O 2 during administration of phenylephrine were excluded for two subjects due to signal error probably because the sensor was not secured.
Phenylephrine
The MAP and TPR increased by 16 and 6 mm Hg min litre 21 , respectively, and SV increased along with a reduction in HR (Table 1 ; n¼10). Phenylephrine reduced S fore O 2 and S invos O 2 by 6.9 (95% confidence interval: 4.8-9.0%; P,0.0001) and 10.5 (8.2 -12.9%; P,0.0001; n¼9), but S av O 2 and S skin O 2 (n¼8) were not affected significantly (Fig. 1) . Phenylephrine also reduced ECAf by 17 (6 -28%; P¼0.0001; n¼7) but increased ICAf by 13 (5 -21%; P¼0.003) leaving VAf, MCAv mean , and SkBF unchanged ( Fig. 2 and Table 1) .
Ephedrine
There was an increase in MAP, CO, and HR by 18 mm Hg, 1.5 litre min 21 , and 12 bpm, respectively, and TPR was reduced by were not changed while S invos O 2 (0.7-4.5%; P¼0.01; n¼9) and S av O 2 (0.5-3.3%; P¼0.01; n¼10) decreased (Fig. 1) .
With ephedrine ICAf and VAf did not change, but ECAf increased by 11% (4-18%; P¼0.005) ( Fig. 2; n¼7) . MCAv mean and SkBF were maintained, but ephedrine provoked a slight ) and ephedrine (1 mg ml 21 ) (n ¼ 7). ICAf, blood flow of the internal carotid artery; ECAf, blood flow of the external carotid artery; VAf, blood flow of the vertebral artery. decrease in Pa CO 2 (P¼0.003). Plasma norepinephrine increased from 4.7 (1.0) to 23.6 (7.5) nM (P¼0.004).
Hyperventilation
There was a reduction in Pa CO 2 by 2.9 kPa and S av O 2 was reduced by 16 
Discussion
The important finding of this study is that ephedrine increased ECAf without affecting ICAf or VAf, or MCAv mean . The SRapparatus applied here aims to suppress influence from extra-cerebral blood flow albeit by use of different sensorconfigurations. 25 Yet, both Foresight and Invos-5100c failed to reflect only oxygenated blood within cerebral tissue, although they were sensitive to reduction in an arterial to jugular derived estimate of cerebral oxygenation (S av O 2 ) with hyperventilation. With phenylephrine both S fore O 2 and S invos O 2 followed changes in ECAf rather than in ICAf and S av O 2 , while during administration of ephedrine, both S fore O 2 and S invos O 2 corresponded to the reduction in S av O 2 , likely explained by the lower Pa CO 2 . Thus, excluding the confounding effect of Pa CO 2 by maintaining ventilation stable (during anaesthesia) SR-NIRS is not changed by administration of ephedrine. 12 13 It is debated whether the reduction in S c O 2 during administration of the selective alpha-agonist phenylephrine is explained by either the reduction in CO or by cerebral vasoconstriction. 11 -14 A low CO appears to influence CBF 26 and phenylephrine might have a different impact on CO depending on its influence on cardiac preload. 27 In supine healthy humans, however, we find it unlikely that phenylephrine reduced CO to an extent that influences cerebral oxygen delivery (i.e. ICAf increased and VAf and MCAv mean were maintained in confirmation of previous findings). 16 Sympathetic influence on CBF remains controversial 14 28 29 and it is unlikely that phenylephrine induces cerebral vasoconstriction. The distribution of alpha-receptors varies along the vasculature 30 and this study suggests that alpha-receptors are richly distributed within the vasculature of the forehead. Ephedrine has an indirect sympathomimetic effect, 31 demonstrated as a five-fold increase in plasma norepinephrine that, however, did not manifest as a reduction in ECAf. Yet, ephedrine increased cerebrovascular resistance by reducing Pa CO 2 . Therefore, the increase in ECAf with ephedrine reflects redistribution of blood from ICA to ECA while phenylephrine increased the resistance of the extracerebral vasculature and blood was shifted from ECA to ICA. The main focus of this study was on the effect of ephedrine and phenylephrine on the intra-vs extra-cerebral circulation and on S c O 2 , but the effect of sympathomimetic agents on perfusion of the liver, kidney, and intestine is of interest for organ function. 32 It is suggested that the brain can be used as an 'index' organ 33 for how well the circulation is handled during surgery. Although S c O 2 is influenced by extra-cerebral blood flow, 15 25 perioperative maintained S c O 2 improves outcomes. 5 6 34 35 To maximize flow-related variables during anaesthesia, it is important to maintain central blood volume, 4 and it could be that focus should be on SkBF because it is markedly influenced by central blood volume. 36 Also, when central blood volume is challenged, there is little effect on CBF and S c O 2 does not necessarily provide information regarding flow to other organs. 37 38 If NIRS is used to guide intraoperative optimization of cerebral oxygenation, 39 the impact of vasopressors on the NIRS signal should be addressed. 6 Thus, it is important to rule out the effect of vasopressors on the NIRS signal when 'time of cerebral deoxygenation' is used (e.g. for comparison of control and intervention groups). 6 7 34 Commercially available SR-NIRS apparatus often claims to provide an absolute value for cerebral oxygenation, but even in homogenous tissue such as skeletal muscle the absolute value provided by SR-NIRS is disputed. 40 However, changes in S c O 2 seem more important for interpretation of oxygen delivery. 39 The penetration depth for light is proportional to the emitter-detector distance (1 of 3 to 1 of 2 of that distance). 41 The Invos has a 4 cm distance from the emitter to the detector, whereas the Foresight device employs 5 cm and should therefore reach more brain tissue. The detector-detector distances are 1 cm (Invos) and 3.5 cm (Foresight), but although Foresight employs both a large penetration depth and detector-detector separation, S fore O 2 was reduced during administration of phenylephrine. An emitter-detector separation of 4 cm should be sufficient to reach the brain from the forehead in healthy subjects 42 but might not be in (elderly) patients presenting cerebral atrophy. Also, oxygenation of blood in subcutaneous tissue and the skull remains to be quantified for eventual contribution to S c O 2 , and we assumed that they are correlated with ECAf and S skin O 2 .
The wavelengths used for SR-NIRS often include about 810 mm to address the isobestic point where O 2 Hb and HHb have similar absorptivity. Some SR-NIRS machines utilize several wavelengths to improve accuracy or to allow calculation of additional components, 43 here exemplified by the Foresight that uses four wavelengths while Invos uses only two. Yet, the Foresight demonstrated a 'CO 2 reactivity' of only 1.6% kPa 21 compared with 2.6% kPa 21 for the Invos and, to our surprise, the Foresight system appeared to have a lower sensitivity to changes in both extracranial and brain oxygenation than the Invos.
Limitations
We have addressed some limitations of the Foresight and Invos-5100c. The algorithms and assumption made by the SR-machines applied here are not disclosed, which limits a thorough sensitivity profile. If SR-NIRS is to report oxygenated haemoglobin within the brain only, the optimal emitterdetector separation, the wavelengths, and perhaps integration of white light spectroscopy to exclude a superficial contribution to S c O 2 should be addressed. We did not observe significant reduction in S skin O 2 and SkBF during administration of phenylephrine, possibly attributable to movement of the sensor causing large SDs. However, we believe that extracerebral blood flow was reduced with phenylephrine as demonstrated by ECAf. We used a fixed 25:75 ratio as a reference for SR-NIRS 24 albeit the optimal reference might depend on both extra-cerebral blood flow and cerebral blood volume. 44 Also, the administered sympathomimetic agents might affect brain microcirculation 45 and we did not perform a CO 2 -correction with the use of ephedrine.
Conclusion
The results indicate that a larger penetration depth and additional wavelengths do not necessarily attenuate an extracerebral contribution to SR-NIRS-derived S c O 2 . Thus, phenylephrine increases internal carotid blood flow and S c O 2 is reduced as external carotid blood flow decreases. On the other hand, ephedrine increases cerebrovascular resistance by reducing Pa CO 2 , but S c O 2 is largely maintained because of an increase in external carotid blood flow.
